CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which missed the analyst consensus estimate of $12.308 million by 88.48 percent. This is a 92.40 percent decrease over sales of $18.658 million the same period last year.